Month: May 2018

Sarepta Therapeutics recently announced a partnership with Myonexus Therapeutics focused on developing gene therapies for five subtypes of LGMD: 2B, 2C, 2D, and 2L. The agreement states that Sarepta will make an upfront payment of $60 million. If development-related milestones